Literature DB >> 33725213

Upregulation of CPNE3 suppresses invasion, migration and proliferation of glioblastoma cells through FAK pathway inactivation.

Dijian Shi1, Bo Lin1, Jun Lai1, Kaipeng Li1, Yimo Feng2.   

Abstract

Glioblastoma (GBM) is a deadly brain tumor with a bleak prognosis. In recent years, the copine III (CPNE3) protein was discovered to be associated to metastasis across various types of malignancies. Nevertheless, its function has not been well documented in glioma. This study characterizes CPNE3 expression in GBM along with its impact and underlying molecular mechanism with regards to cellular migration, invasion and proliferation. Immunohistochemistry was used to characterizes CPNE3 expression in the glioma tissues. Then, knockdown of CPNE3 expression was used to analyze the role of CPNE3 in GBM cell viability, migration, invasion. Western blot analysis was performed to measure the protein levels of FAK signaling pathway. We found that GBM tissues had higher CPNE3 expressions as compared to those in normal brain tissues. CPNE3 silencing in GBM cells impaired the migratory, invasive and proliferative abilities of GBM cells that can be attributed to inactivation of the FAK signaling pathway. Collectively, these findings highlight the role of CPNE3 as a new biomarker, offering deeper insights into its carcinogenic role in GBM.

Entities:  

Keywords:  CPNE3; FAK signaling pathway; Glioblastoma; Invasion

Year:  2021        PMID: 33725213     DOI: 10.1007/s10735-021-09966-0

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  23 in total

1.  Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.

Authors:  G Jones; J Machado; A Merlo
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 2.  Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance.

Authors:  Jonathan Cooper; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

3.  Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival.

Authors:  Lianshu Ding; Xiaoyang Sun; Yongping You; Ning Liu; Zhen Fu
Journal:  Transl Res       Date:  2010-05-26       Impact factor: 7.012

4.  Direct binding of Copine3 with Jab1 activates downstream ErbB2 signaling and motility in SKBr3 breast cancer cells.

Authors:  Hye Young Choi; Nammi Park; Jae Boem Na; Eun Sook Ko; Jae-Yong Park; Jae Cheal Yoo
Journal:  Oncol Rep       Date:  2015-12-02       Impact factor: 3.906

Review 5.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

6.  Copine-III interacts with ErbB2 and promotes tumor cell migration.

Authors:  C Heinrich; C Keller; A Boulay; M Vecchi; M Bianchi; R Sack; S Lienhard; S Duss; J Hofsteenge; N E Hynes
Journal:  Oncogene       Date:  2009-12-14       Impact factor: 9.867

Review 7.  Every step of the way: integrins in cancer progression and metastasis.

Authors:  Hellyeh Hamidi; Johanna Ivaska
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

8.  Tumour exosome integrins determine organotropic metastasis.

Authors:  Ayuko Hoshino; Bruno Costa-Silva; Tang-Long Shen; Goncalo Rodrigues; Ayako Hashimoto; Milica Tesic Mark; Henrik Molina; Shinji Kohsaka; Angela Di Giannatale; Sophia Ceder; Swarnima Singh; Caitlin Williams; Nadine Soplop; Kunihiro Uryu; Lindsay Pharmer; Tari King; Linda Bojmar; Alexander E Davies; Yonathan Ararso; Tuo Zhang; Haiying Zhang; Jonathan Hernandez; Joshua M Weiss; Vanessa D Dumont-Cole; Kimberly Kramer; Leonard H Wexler; Aru Narendran; Gary K Schwartz; John H Healey; Per Sandstrom; Knut Jørgen Labori; Elin H Kure; Paul M Grandgenett; Michael A Hollingsworth; Maria de Sousa; Sukhwinder Kaur; Maneesh Jain; Kavita Mallya; Surinder K Batra; William R Jarnagin; Mary S Brady; Oystein Fodstad; Volkmar Muller; Klaus Pantel; Andy J Minn; Mina J Bissell; Benjamin A Garcia; Yibin Kang; Vinagolu K Rajasekhar; Cyrus M Ghajar; Irina Matei; Hector Peinado; Jacqueline Bromberg; David Lyden
Journal:  Nature       Date:  2015-10-28       Impact factor: 49.962

9.  High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia.

Authors:  Lin Fu; Huaping Fu; Jianlin Qiao; Yifan Pang; Keman Xu; Lei Zhou; Qingyun Wu; Zhenyu Li; Xiaoyan Ke; Kailin Xu; Jinlong Shi
Journal:  Cancer Sci       Date:  2017-08-20       Impact factor: 6.716

10.  MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling.

Authors:  Ke Jiang; Gang Yao; Lulu Hu; Yumei Yan; Jia Liu; Ji Shi; Youwei Chang; Ye Zhang; Dapeng Liang; Dachuan Shen; Guirong Zhang; Songshu Meng; Haozhe Piao
Journal:  Cell Death Dis       Date:  2020-04-14       Impact factor: 8.469

View more
  3 in total

1.  CPNE3 interaction with RACK1 protects against myocardial ischemia/reperfusion injury.

Authors:  Xiaoqun Zhang; Xue Han; Yanan Zhang
Journal:  Exp Ther Med       Date:  2021-12-10       Impact factor: 2.447

2.  Copine 3 "CPNE3" is a novel regulator for insulin secretion and glucose uptake in pancreatic β-cells.

Authors:  Waseem El-Huneidi; Shabana Anjum; Abdul Khader Mohammed; Hema Unnikannan; Rania Saeed; Khuloud Bajbouj; Eman Abu-Gharbieh; Jalal Taneera
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

3.  miRNome and Proteome Profiling of Small Extracellular Vesicles Secreted by Human Glioblastoma Cell Lines and Primary Cancer Stem Cells.

Authors:  Ingrid Cifola; Federica Fratini; Beatrice Cardinali; Valentina Palmieri; Giuliana Gatti; Tommaso Selmi; Sara Donzelli; Andrea Sacconi; Valeriana Cesarini; Hany E Marei; Massimilano Papi; Giovanni Blandino; Carlo Cenciarelli; Germana Falcone; Igea D'Agnano
Journal:  Biomedicines       Date:  2022-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.